Progress Report On UK's Early Access Scheme: A Limited Success But Could Do Better
This article was originally published in SRA
The UK's early access to medicines scheme (EAMS) has been operational for two years, along with a "promising innovative medicine" (PIM) designation, to give patients timely access to new drugs for serious diseases before they are approved. The system has now been independently reviewed. Sten Stovall talks to those in the industry that have first-hand experience of the process.
Register for our free email digests: